Signal Desk · Markets

Alkem Laboratories gets USFDA warning letter for Daman facility

2026-11-19 · 1 source · CNBC TV18 Market

In short

Alkem Laboratories got a USFDA warning letter for its Daman facility and was classified as OAI. The company said it will reply to the regulator within the given timeline.

It also said the facility keeps making and supplying approved products to the US market.

What the reporting says

Alkem Laboratories received a USFDA warning letter and an OAI classification for its Daman facility, according to the headline and summary provided. The company said it will respond to the USFDA within the stipulated timeline. It also said it continues to manufacture and supply approved products from the facility to the US market, indicating ongoing operations despite the regulatory action.

Why it matters

Alkem Laboratories received a USFDA warning letter with OAI classification for its Daman facility. The company said it will respond within the stipulated timeline and that the facility continues to manufacture and supply approved products to the US market. The regulatory notice is relevant for Alkem’s US-facing operations and may keep investors focused on compliance and supply continuity.

Touches: Alkem Laboratories, Healthcare, Markets, Companies

Sources